| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial RS Bresalier, RS Sandler, H Quan, JA Bolognese, B Oxenius, K Horgan, ... New England Journal of Medicine 352 (11), 1092-1102, 2005 | 3296 | 2005 |
| The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. GA Van Seventer, Y Shimizu, KJ Horgan, S Shaw Journal of immunology (Baltimore, Md.: 1950) 144 (12), 4579-4586, 1990 | 1020 | 1990 |
| The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial … PJ Hesketh, SM Grunberg, RJ Gralla, DG Warr, F Roila, R De Wit, ... Journal of clinical oncology 21 (22), 4112-4119, 2003 | 957 | 2003 |
| Regulated expression and binding of three VLA (β1) integrin receptors on T cells Y Shimizu, GAV Seventer, KJ Horgan, S Shaw Nature 345 (6272), 250-253, 1990 | 826 | 1990 |
| Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting: Results from a … S Poli‐Bigelli, J Rodrigues‐Pereira, AD Carides, G Julie Ma, K Eldridge, ... Cancer 97 (12), 3090-3098, 2003 | 699 | 2003 |
| Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab WJ Sandborn, P Rutgeerts, BG Feagan, W Reinisch, A Olson, J Johanns, ... Gastroenterology 137 (4), 1250-1260, 2009 | 587 | 2009 |
| Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy DG Warr, PJ Hesketh, RJ Gralla, HB Muss, J Herrstedt, PD Eisenberg, ... Journal of Clinical Oncology 23 (12), 2822-2830, 2005 | 564 | 2005 |
| A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas JA Baron, RS Sandler, RS Bresalier, H Quan, R Riddell, A Lanas, ... Gastroenterology 131 (6), 1674-1682, 2006 | 556 | 2006 |
| Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. Y Shimizu, GA Van Seventer, KJ Horgan, S Shaw Journal of immunology (Baltimore, Md.: 1950) 145 (1), 59-67, 1990 | 469 | 1990 |
| CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. Y Tanaka, SM Albelda, KJ Horgan, GA Van Seventer, Y Shimizu, ... The Journal of experimental medicine 176 (1), 245-253, 1992 | 460 | 1992 |
| Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions. Y Shimizu, W Newman, TV Gopal, KJ Horgan, N Graber, LD Beall, ... The Journal of cell biology 113 (5), 1203-1212, 1991 | 456 | 1991 |
| Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding … Y Shimizu, GA Van Seventer, KJ Horgan, S Shaw Immunological reviews 114, 109-143, 1990 | 397 | 1990 |
| Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion … GA van Seventer, W Newman, Y Shimizu, TB Nutman, Y Tanaka, ... The Journal of experimental medicine 174 (4), 901-913, 1991 | 344 | 1991 |
| Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism. T Schweighoffer, Y Tanaka, M Tidswell, DJ Erle, KJ Horgan, GE Luce, ... Journal of immunology (Baltimore, Md.: 1950) 151 (2), 717-729, 1993 | 316 | 1993 |
| Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists PJ Hesketh, S Van Belle, M Aapro, FD Tattersall, RJ Naylor, ... European journal of cancer 39 (8), 1074-1080, 2003 | 309 | 2003 |
| Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting SP Chawla, SM Grunberg, RJ Gralla, PJ Hesketh, C Rittenberg, ME Elmer, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 269 | 2003 |
| A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting TJ Gan, CC Apfel, A Kovac, BK Philip, N Singla, H Minkowitz, AS Habib, ... Anesthesia & Analgesia 104 (5), 1082-1089, 2007 | 237 | 2007 |
| Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion. Y Shimizu, GA Van Seventer, E Ennis, W Newman, KJ Horgan, S Shaw The Journal of experimental medicine 175 (2), 577-582, 1992 | 232 | 1992 |
| Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin … R De Wit, J Herrstedt, B Rapoport, AD Carides, G Carides, M Elmer, ... Journal of clinical oncology 21 (22), 4105-4111, 2003 | 185 | 2003 |
| The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo … DG Warr, SM Grunberg, RJ Gralla, PJ Hesketh, F Roila, R De Wit, ... European Journal of Cancer 41 (9), 1278-1285, 2005 | 173 | 2005 |
